COMPASS Pathways plc to participate in HC Wainwright and ICR investor conferences

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in two investor conferences during the week of 11 January 2021.

George Goldsmith, Chairman, CEO and Co‑founder, and Lars Wilde, President, Chief Business Officer, and Co‑founder, will be participating in a fireside chat available on demand from 11 to 14 January in conjunction with the HC Wainwright BioConnect 2021 Conference.

George Goldsmith and Lars Wilde will also present a business update and hold a fireside chat at 12:15 pm ET on 14 January at the Westwicke Healthcare Day at the ICR Conference 2021.

Audio webcasts of the fireside chats will be available on the "Events" page of the Investors section of the COMPASS website at https://ir.compasspathways.com/news-events/events. A replay of events will be available for 30 days following the event.

-Ends-

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 21 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing. www.compasspathways.com

Contacts:

Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401-290-7324





Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Dried mushrooms in the center are surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, Risks Remain

On April 18, President Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments For Serious Mental Illness, an executive order to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as an alternative... Keep Reading...
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...
Emyria Limited

Emyria Launches Global Services Platform Targeting International Drug Sponsors

Emyria’s established, world-first, unique national clinical delivery network to drive a new services-led revenue stream focused on global drug sponsors.

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce the launch of its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access Emyria’s established clinical delivery... Keep Reading...
Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with an emphasis on safe, evidence-based psychedelic-assisted therapies, is providing an update regarding its listing status on the... Keep Reading...
Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update

Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Corporate UpdateOver the past year,... Keep Reading...
Numinus Wellness Advises of a Change of Auditor

Numinus Wellness Advises of a Change of Auditor

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is advising of a change of its auditor. The Company's previous... Keep Reading...

Interactive Chart

Latest Press Releases

Related News